Revised SPC: Vidaza (azacitidine) 25 mg/ml powder for suspension for injection

Source:
electronic Medicines Compendium - eMC
Publisher:
electronic Medicines compendium
Publication date:
16 April 2019

Abstract

Pericarditis has been added as an uncommon adverse event.